TRMT13

Across TCGA pan-cancer cohorts, TRMT13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRMT13 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TRMT13 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRMT13 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where TRMT13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.907	0.649	.019	16	view →
HNSC	DFS	Median	III,IV	0.661	0.939	.003	8	view →
CCRCC	DFS	Median	III,IV	0.842	1.000	.026	4	view →
PDAC	DFS	Median	IV	0.741	0.214	.017	3	view →
LUAD	DFS	Quartile	II,III,IV	0.899	0.738	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRMT13–LSCC (OS)

Open the LSCC breakdown →